In the Specification:

Please amend the specification as follows:

On Page 1, line 1, after the title, insert the following paragraph:

— **RELATED APPLICATIONS**

This a **Continuation** of U.S. Application Serial No. 09/610,785 filed July 6, 2000, which is a Continuation of U.S. Application Serial No. 09/299,319 filed April 26, 1999 which is a Continuation of U.S. Application Serial No. 09/063,465 filed April 20, 1998 which is a Continuation of U.S. Application Serial No. 08/644,290 filed May 10, 1996. —

The paragraph beginning at Page 25, line 13 has been substituted with the following:

-- A tube assay was used to determine the effects of a BPI protein product on clot formation and on clot lysis or dissolution under a variety of conditions using human plasma samples. Unless otherwise noted the human plasma used in these assays was prepared from human blood drawn from a variety of donors into ACD VACUTAINER® blood collection device ~~Vacutainer®~~ tubes (Becton Dickinson, Mountainview, CA) containing citrate as an anticoagulant, and was stored frozen at -70°C. For the preparation of platelet rich plasma (PRP), the anticoagulated blood was centrifuged at approximately 180 x g for 5 minutes and the plasma removed following this low-speed centrifugation. For the preparation of platelet poor plasma (PPP), the anticoagulated blood was centrifuged at approximately 460 x g for 10 minutes and the plasma removed following this higher speed centrifugation. --

The paragraph at Page 37, line 14 has been substituted with the following:

-- Clot formation was evaluated with $rBPI_{21}$ and freshly collected blood. For this experiment, blood was collected into four siliconized 3 mL VACUTAINER® blood collection device ~~Vacutainer®~~ tubes containing either 50, 100, 200 μg/ml $rBPI_{21}$ or control

formulation buffer. Each tube was inverted several times after blood collection and placed on ice until blood had been collected for all tubes. (Collection time of each tube was less than thirty seconds.) --